NASDAQ:PTX Pernix Therapeutics (PTX) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free PTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.03▼$0.2152-Week Range N/AVolume16,105 shsAverage Volume3.04 million shsMarket Capitalization$419,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Pernix Therapeutics alerts: Email Address Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Pernix Therapeutics Stock (NASDAQ:PTX)Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry. The company's products comprise Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet, a fixed dose combination product indicated for the treatment of acute migraine. Pernix Therapeutics Holdings, Inc. markets and sells its non-core products, including generics through its wholly owned subsidiaries; and markets its non-promoted products through distributors and trade partners. It serves drug wholesalers, specialty pharmacies, retail drug stores, mass merchandisers, and grocery store pharmacies. Pernix Therapeutics Holdings, Inc. was founded in 1996 and is headquartered in Morristown, New Jersey.Read More Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. PTX Stock News HeadlinesFebruary 23, 2024 | morningstar.comBicycle Therapeutics PLC ADR BCYCSeptember 26, 2022 | reuters.comPrescient Therapeutics LtdMay 4, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” August 25, 2022 | yahoo.comThose who invested in Prescient Therapeutics (ASX:PTX) three years ago are up 307%April 6, 2022 | msn.comA Builder From The Ground Up, Doug Drysdale, CEO of Cybin: Meet Our SpeakersMarch 30, 2022 | investing.comPernix Therapeutics Holdings Inc (PTX)October 26, 2021 | finance.yahoo.comMid-Afternoon Market Update: Vivint Solar Dips After Wider-Than-Expected Q3 Loss; Rackspace Shares Spike HigherSee More Headlines Receive PTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pernix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:PTX CUSIP71426V10 CIK1024126 Webwww.pernixtx.com Phone800-793-2145FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-77,140,000.00 Net Margins-59.70% Pretax MarginN/A Return on EquityN/A Return on Assets-37.01% Debt Debt-to-Equity RatioN/A Current Ratio1.08 Quick Ratio0.92 Sales & Book Value Annual Sales$146.07 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($14.77) per share Price / BookN/AMiscellaneous Outstanding Shares14,510,000Free FloatN/AMarket Cap$419,000.00 OptionableOptionable Beta1.20 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. John Anthony Sedor (Age 74)Chairman & CEO Mr. Kenneth R. Pina Esq. (Age 60)Sr. VP, Chief Legal & Compliance Officer and Corp. Sec. Mr. Glenn Whaley (Age 51)VP of Fin., Principal Financial & Accounting Officer Mr. Anthony M. OrricoVP of Technical & Supply OperationsMr. George P. JonesVP of Sales & MarketingKey CompetitorsChina SXT PharmaceuticalsNASDAQ:SXTCAthersysNASDAQ:ATHXAptevo TherapeuticsNASDAQ:APVOAmpio PharmaceuticalsNYSE:AMPEAditxtNASDAQ:ADTXView All Competitors PTX Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Pernix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Pernix Therapeutics investors own include PIMCO High Income Fund (PHK), Synergy Pharmaceuticals (SGYP), Investors Bancorp (ISBC), Novavax (NVAX), Gevo (GEVO), Amira Nature Foods (ANFI), Argos Therapeutics (ARGSQ), Catalyst Pharmaceuticals (CPRX), (GBSN) (GBSN) and (FPP) (FPP). This page (NASDAQ:PTX) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCFW: 234x GainWeiss RatingsCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pernix Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.